The global Parkinson’s disease treatment market size was estimated to be USD 5.38 billion in 2023 and is expected to reach at USD 19.01 billion by 2034 with a CAGR of 12.16% during the forecast period 2024-2034. Rising geriatric population, growing prevalence of Parkinson’s Disease (PD), the strong product pipeline of disease-modifying therapies, surge in favorable healthcare reimbursement policies, increasing research & development activities, rising focus on the development of novel medications, growing investment by leading market players, and surge in number of clinical trial procedures are some of the key factors boosting the market growth.
Surge in number of clinical trial procedures is predicted to boost the market growth during the forecast period. Parkinson's disease is a neurological condition that impairs the ability to control movements. It results from the deterioration or damage of nerve cells (neurons) in the substantia nigra (SN) region of the brain. Typically, the condition progresses slowly and worsens over time. Key symptoms of Parkinson's disease include tremors, muscle stiffness, difficulty with movement, balance issues, and coordination problems. As the disease advances, individuals may also experience difficulties with speech and sleep, cognitive impairment, and behavioral changes. Managing chronic Parkinson's disease necessitates prolonged treatment and specialized care. Consequently, industry stakeholders are placing emphasis on the development of innovative treatment options for this condition. For instance, in January 2023, NeuroDerm Ltd. has reported very promising outcomes from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial. This trial assessed ND0612, a continuous 24-hour subcutaneous infusion of liquid levodopa/carbidopa (LD/CD), for Parkinson's Disease (PD) patients experiencing motor fluctuations. The trial successfully achieved its primary objective of increasing "Good ON" time in these patients.
By drug class, carbidopa-levodopa was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the substantial frequency of prescriptions for these medications and increasing research & development activities. For instance, in May 2022, AbbVie Inc. has filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) for ABBV-951, which consists of foscarbidopa/foslevodopa, as a potential treatment for motor fluctuations in patients with advanced Parkinson's Disease. Additionally, MAO-B inhibitors is predicted to grow at fastest CAGR during the forecast period owing to the existence of potential candidates in the development pipeline and rising approval of novel treatment options for the disease.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the most of the use of this medication is linked to retail pharmacies, the convenient accessibility of Parkinson's disease drugs, including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, & others, at retail pharmacy chains, and rising collaborations within market players. For instance, In June 2022, Biogen Inc. and Alectos Therapeutics have entered into a collaboration agreement aimed at jointly developing and bringing to market GBA2 inhibitors, represented by AL01811, as a prospective treatment for individuals with Parkinson's Disease (PD). This partnership grants Biogen the global rights for developing, manufacturing, and commercializing AL01811. 3Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing popularity of online shopping is a result of the comfort, flexibility, & convenience provided by these platforms, online shopping provides customers with various discounts, delivering advantages to them.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, rising introduction of new products for managing symptoms of Parkinson's disease, and surge in number of clinical trial procedures. For instance, in January 2022, BlueRock Therapeutics, a clinical-stage biopharmaceutical company and a subsidiary of Bayer AG, has initiated the administration of the initial dose of DA01, which comprises dopaminergic neurons, to patients with advanced Parkinson's Disease (PD) in Canada. This significant development is a collaborative effort with the University Health Network. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the higher product adoption, unexplored opportunities, rising number of individuals affected by Parkinson's disease, and growing collaborations within market players. For instance, in January 2022, Iktos, a company based in South Korea with expertise in artificial intelligence (AI) for the creation of new drug designs, has partnered with Astrogen, a biotech company specializing in clinical and research-oriented development of groundbreaking drugs for the treatment of challenging neurological diseases. Together, they have entered into a research collaboration agreement with the goal of identifying novel small molecule pre-clinical drug candidates for Parkinson's disease.
Surge in number of clinical trial procedures is predicted to boost the market growth during the forecast period. Parkinson's disease is a neurological condition that impairs the ability to control movements. It results from the deterioration or damage of nerve cells (neurons) in the substantia nigra (SN) region of the brain. Typically, the condition progresses slowly and worsens over time. Key symptoms of Parkinson's disease include tremors, muscle stiffness, difficulty with movement, balance issues, and coordination problems. As the disease advances, individuals may also experience difficulties with speech and sleep, cognitive impairment, and behavioral changes. Managing chronic Parkinson's disease necessitates prolonged treatment and specialized care. Consequently, industry stakeholders are placing emphasis on the development of innovative treatment options for this condition. For instance, in January 2023, NeuroDerm Ltd. has reported very promising outcomes from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial. This trial assessed ND0612, a continuous 24-hour subcutaneous infusion of liquid levodopa/carbidopa (LD/CD), for Parkinson's Disease (PD) patients experiencing motor fluctuations. The trial successfully achieved its primary objective of increasing "Good ON" time in these patients.
By drug class, carbidopa-levodopa was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the substantial frequency of prescriptions for these medications and increasing research & development activities. For instance, in May 2022, AbbVie Inc. has filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) for ABBV-951, which consists of foscarbidopa/foslevodopa, as a potential treatment for motor fluctuations in patients with advanced Parkinson's Disease. Additionally, MAO-B inhibitors is predicted to grow at fastest CAGR during the forecast period owing to the existence of potential candidates in the development pipeline and rising approval of novel treatment options for the disease.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the most of the use of this medication is linked to retail pharmacies, the convenient accessibility of Parkinson's disease drugs, including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, & others, at retail pharmacy chains, and rising collaborations within market players. For instance, In June 2022, Biogen Inc. and Alectos Therapeutics have entered into a collaboration agreement aimed at jointly developing and bringing to market GBA2 inhibitors, represented by AL01811, as a prospective treatment for individuals with Parkinson's Disease (PD). This partnership grants Biogen the global rights for developing, manufacturing, and commercializing AL01811. 3Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing popularity of online shopping is a result of the comfort, flexibility, & convenience provided by these platforms, online shopping provides customers with various discounts, delivering advantages to them.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, rising introduction of new products for managing symptoms of Parkinson's disease, and surge in number of clinical trial procedures. For instance, in January 2022, BlueRock Therapeutics, a clinical-stage biopharmaceutical company and a subsidiary of Bayer AG, has initiated the administration of the initial dose of DA01, which comprises dopaminergic neurons, to patients with advanced Parkinson's Disease (PD) in Canada. This significant development is a collaborative effort with the University Health Network. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the higher product adoption, unexplored opportunities, rising number of individuals affected by Parkinson's disease, and growing collaborations within market players. For instance, in January 2022, Iktos, a company based in South Korea with expertise in artificial intelligence (AI) for the creation of new drug designs, has partnered with Astrogen, a biotech company specializing in clinical and research-oriented development of groundbreaking drugs for the treatment of challenging neurological diseases. Together, they have entered into a research collaboration agreement with the goal of identifying novel small molecule pre-clinical drug candidates for Parkinson's disease.
Segmentation: Parkinson’s Disease Treatment Market Report 2023 - 2034
Parkinson’s Disease Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Dopamine Agonists
- MAO-B Inhibitors
- Carbidopa-levodopa
- Anticholinergics
- COMT Inhibitors
- Others
Parkinson’s Disease Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Parkinson’s Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Parkinson’s Disease Treatment Market: Drug Class Estimates & Trend Analysis
8. Parkinson’s Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Parkinson’s Disease Treatment Market
11. Europe Global Parkinson’s Disease Treatment Market
12. Asia Pacific Global Parkinson’s Disease Treatment Market
13. Latin America Global Parkinson’s Disease Treatment Market
14. MEA Global Parkinson’s Disease Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Supernus Pharmaceuticals Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- GlaxoSmithKline plc. (GSK)
- AbbVie Inc.
- Cerevel Therapeutics
- H. Lundbeck A/S
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.38 Billion |
| Forecasted Market Value ( USD | $ 19.01 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
